Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
Quick Look: Sawai has accepted Merck’s claims in a Tokyo patent suit over its Januvia generics. Generic entry is now likely on hold until patent expiry, though Sawai says its IP strategy is unchanged. ----- Sawai Group Holdings has effectively…
To read the full story
Related Article
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
- Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
August 16, 2023
BUSINESS
- BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
- Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
May 21, 2026
- Myelofibrosis Med Inrebic to Go on Sale June 1: Recordati Japan
May 21, 2026
- Fujifilm Opens New US Facility, Expands iPSC-Derived Cell Production
May 21, 2026
- High-Dose Uptravi Now Available: Nippon Shinyaku
May 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…